ATEM Capital is a Life Sciences investment fund focusing on biotech innovations in the US and Europe. The firm targets breakthrough technologies addressing unmet clinical needs, with strong IP protection and potential for strategic acquisition. ATEM Capital typically invests in Series A and Series B rounds, consolidating capital flows from emerging markets to invest in established biotech hubs.
The firm's portfolio includes notable companies such as Arpeggio Bio, Iridia, and Triumvira Immunologics. ATEM Capital's international team brings extensive experience in investment, science, legal matters, and portfolio risk management. The fund is audited by a Big-4 firm and benefits from an Advisory Board comprising high-caliber entrepreneurs and VC veterans, offering valuable insights and connections to portfolio companies.
Atem Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies3
Current Portfolio Count3
Top Investment Stages
Series A2 (66.7%)
Series B1 (33.3%)
Stage Mix
Series A 67%Series B 33%
Concentration shown as share of disclosed investments by stage.
